Pharmaceuticals, Biotechnology and Life Sciences
BARCELONA, Spain–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new two-year data from the long-term extension of…
NeuClone starts dosing NeuLara ustekinumab the first patients, a Johnson and Johnson’s Stelara biosimilar candidate, in a Phase I clinical…
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has approved the expanded use of ustekinumab for the treatment of adults with moderately to severely active ulcerative colitis (UC), who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
Novartis has had Cosentyx compared against Janssen’s IL-23 Stelara, and it showed superior improvements for psoriasis patients, it said in a statement Tuesday, noting that it was processed and transmitted by West Corporation.
Janssen Biotech is looking to expand the usage of its prescription drug Stelara, as it has asked the U.S. Food…
Janssen Biotech, Inc. and Janssen-Cilag International NV (Janssen) are seeking approval from the U.S. and European authorities for Chron’s disease drug Stelara.